BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36835612)

  • 1. Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model.
    Lai JI; Porcu A; Romoli B; Keisler M; Manfredsson FP; Powell SB; Dulcis D
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
    Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
    J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nurr1 in Parkinson's disease and related disorders.
    Chu Y; Le W; Kompoliti K; Jankovic J; Mufson EJ; Kordower JH
    J Comp Neurol; 2006 Jan; 494(3):495-514. PubMed ID: 16320253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up and Down γ-Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice.
    Pavia-Collado R; Rodríguez-Aller R; Alarcón-Arís D; Miquel-Rio L; Ruiz-Bronchal E; Paz V; Campa L; Galofré M; Sgambato V; Bortolozzi A
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
    Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
    Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
    Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.
    Kandil EA; Sayed RH; Ahmed LA; Abd El Fattah MA; El-Sayeh BM
    Mol Neurobiol; 2018 May; 55(5):4078-4089. PubMed ID: 28585189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
    Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigrostriatal innervation is preserved in Nurr1-null mice, although dopaminergic neuron precursors are arrested from terminal differentiation.
    Witta J; Baffi JS; Palkovits M; Mezey E; Castillo SO; Nikodem VM
    Brain Res Mol Brain Res; 2000 Dec; 84(1-2):67-78. PubMed ID: 11113533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
    Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
    J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
    Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
    Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.
    Alerte TN; Akinfolarin AA; Friedrich EE; Mader SA; Hong CS; Perez RG
    Neurosci Lett; 2008 Apr; 435(1):24-9. PubMed ID: 18314273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes.
    Zhang W; Zhou M; Lu W; Gong J; Gao F; Li Y; Xu X; Lin Y; Zhang X; Ding L; Zhang Z; Li G; Chen X; Sun X; Zhu X; Xu P; Zhang Y
    Theranostics; 2020; 10(7):3000-3021. PubMed ID: 32194851
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
    Park JS; Choe K; Lee HJ; Park TJ; Kim MO
    J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra.
    Chu Y; Kompoliti K; Cochran EJ; Mufson EJ; Kordower JH
    J Comp Neurol; 2002 Aug; 450(3):203-14. PubMed ID: 12209851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.